ADA

ADA 2023: Findings from a new study show that higher levels of glycemia in childhood are associated with future microvascular complications, such as nephropathy and retinopathy.

ADA 2023. Results from PIONEER PLUS trial showed oral semaglutide 25 mg and 50 mg were superior than 14 mg in reducing HbA1c and body weight in adults with T2D.

ADA 2023: Weight loss with the combination GLP-1/GIP/glucagon receptor agonist was as high as 30% in study participants who received the highest dose.

ADA 2023. Once-daily oral semaglutide 50 mg induced 15.1% weight loss in adults with overweight or obesity without type 2 diabetes vs placebo.

ADA 2023: The investigational oral GLP-1 RA resulted in weight loss comparable to injectable GLP-1 RA formulations and requires no food or water restrictions.

ADA 2023: SURMOUNT-2 findings show tirzepatide is associated with greater weight loss in adults with T2D than any other treatment studied to date.

ADA 2023. Retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, may provide benefits in liver fibrosis and obesity as well as in glycemic control.

ADA 2022: Use of flash continuous glucose monitoring in T2D patients not on insulin also reduced HbA1c and glycemic variability, a new study finds.

ADA 2022: Large national study found that CGM use had a positive effect on glycemic control and acute complications in T2D in the Veterans Health Administration.

ADA 2022. Tirzepatide was associated with significantly greater TIR, many fewer episodes of hypoglycemia, and less glycemic excursion vs insulin degludec in SURPASS-3 CGM.